XML 97 R16.htm IDEA: XBRL DOCUMENT
v3.26.1

Investment in associates | 12 Months Ended
--- | ---
Mar. 31, 2026
Investment In Associates |
Investment in associates |
9. | Investment in associates
Schedule of investment in associates
|  | 2026 |  |  | 2025 |
|  | USD |  |  | USD |
Unquoted shares - at cost |  |  |  |  |  |  |  |
As at April 1 |  |  | 1,493,850 |  |  |  | 1,493,850 |
Unquoted shares - at cost beginning |  |  | 1,493,850 |  |  |  | 1,493,850 |
Disposal during the financial year |  |  | (677 | ) |  |  | - |
Reclassification to Other Investment during the financial year (Note 8) |  |  | (1,492,955 | ) |  |  | - |
As at March 31 |  |  | 218 |  |  |  | 1,493,850 |
Unquoted shares- at cost end |  |  | 218 |  |  |  | 1,493,850 |
Less: Accumulated impairment loss |  |  |  |  |  |  |  |
As at April 1 |  |  | (257 | ) |  |  | (257 | )
Accumulated impairment loss beginning |  |  | (257 | ) |  |  | (257 | )
Reversal of impairment during the financial year |  |  | 263 |  |  |  | - |
Exchange difference |  |  | (6 | ) |  |  | - |
As at March 31 |  |  | - |  |  |  | (257 | )
Accumulated impairment loss ending |  |  | - |  |  |  | (257 | )
Unquoted shares- at cost, net |  |  | 218 |  |  |  | 1,493,593 |
Share of post-acquisition reserve |  |  |  |  |  |  |  |
As at April 1 |  |  | 3,151 |  |  |  | 13,911 |
Share of post-acquisition reserve beginning |  |  | 3,151 |  |  |  | 13,911 |
Share profit((loss) during the financial year |  |  | 14,449 |  |  |  | (10,760 | )
As at March 31 |  |  | 17,600 |  |  |  | 3,151 |
Share of post-acquisition reserve ending |  |  | 17,600 |  |  |  | 3,151 |
Share of post- acquisition reserve, net |  |  | 17,818 |  |  |  | 1,496,744 |
Exchange differences |  |  | 788 |  |  |  | 99,432 |
Investment in associates |  |  | 18,606 |  |  |  | 1,596,176 |
The details of associates are as follows: Schedule of details of associates
|  | Place of business/ Country of |  | Effective equity |  |  |
Name of Company |  | incorporation |  | interest |  |  | Principal activities
|  |  |  | 2026 |  |  | 2025 |  |  |
|  |  |  | % |  |  | % |  |  |
Vax Biotech Sdn. Bhd. (“Vax Biotech”) |  | Malaysia |  |  | - |  |  |  | 30 | % |  | Manufacture of medicaments
Alps Globemedics Sdn. Bhd. (“Alps Globemedics”) |  | Malaysia |  |  | 30 | % |  |  | 30 | % |  | Marketing of health and beauty product and services
Cilo Cybin Holdings Limited (“Cilo Cybin”) |  | South Africa |  |  | - |  |  |  | 40.5 | % |  | Investment in biotech, biohacking and pharmaceutical businesses
Investment in Vax Biotech During the financial year, the Group disposed of its entire equity interest in Vax Biotech for a total consideration of USD0.47. The disposal resulted in a loss of USD677 which has been recognized in “other operating expenses” in the consolidated statements of profit or loss and other comprehensive income (loss) of the Group.
9. | Investment in associates (Cont’d)
Investment in Cilo Cybin During the financial year, Cilo Cybin completed its acquisition of Cilo Cybin Pharmaceutical, which resulted in the enlargement of Cilo Cybin’s issued share capital post-acquisition, thereby reducing the Group’s shareholding to approximately 9.98% of the total issued share capital of the combined post-acquisition entity. Accordingly, the Group’s investment in Cilo Cybin was reclassified from investment in associates to other investment. Investment in Alps Globemedics Summarised financial information of Alps Globemedics is set out below. The summarised financial information represents the amount in the financial statements of the associate and not the Group’s share of those amounts. Schedule of financial information represents the amount in the financial statements
Alps Globemedic Sdn Bhd |  | 2026 |  |  | 2025 |
|  | USD |  |  | USD |
Statement of financial position |  |  |  |  |  |  |  |
Non-current assets |  |  | 3,274 |  |  |  | 3,529 |
Current assets |  |  | 190,038 |  |  |  | 36,502 |
Total assets |  |  | 193,312 |  |  |  | 40,031 |
Current liabilities |  |  | (131,329 | ) |  |  | (16,483 | )
Total liabilities |  |  | (131,329 | ) |  |  | (16,483 | )
Net assets of the associate |  |  | 61,983 |  |  |  | 23,548 |
Statement of comprehensive income |  |  |  |  |  |  |  |
Revenue for the financial year |  |  | 268,615 |  |  |  | 187,465 |
Profit for the financial year |  |  | 34,606 |  |  |  | 7,375 |
Share of profit of the associate |  |  | 10,382 |  |  |  | 2,213 |
Reconciliation of the above summarised financial information to the carrying amount of the interest in associate recognised in the consolidated financial statements: Schedule of financial information to the carrying amount of interest
|  | 2025 |  |  | 2025 |
|  | USD |  |  | USD |
Proportion of net assets of the associate |  |  | 18,595 |  |  |  | 7,421 |
Exchange differences |  |  | 11 |  |  |  | (357 | )
Carrying amount of the Group’s interest in associate |  |  | 18,606 |  |  |  | 7,064 |

X
- References No definition available. + Details
Name: | ALPS_DisclosureOfInvestmentInAssociatesAbstract
Namespace Prefix: | ALPS_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of investment in associates explanatory. + References No definition available. + Details
Name: | ALPS_DisclosureOfInvestmentInAssociatesExplanatory
Namespace Prefix: | ALPS_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration